BTAI (BioXcel Therapeutics) Future 3-5Y EPS without NRI Growth Rate : 35.05 (As of Apr. 12, 2025)

View and export this data going back to 2018. Start your Free Trial

What is BioXcel Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate is 35.05.

Competitive Comparison of BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

BioXcel Therapeutics (NAS:BTAI) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

BioXcel Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of BioXcel Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

BioXcel Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioXcel Therapeutics Inc (NAS:BTAI) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

BX20:Germany

Address

555 Long Wharf Drive, New Haven, CT, USA, 06511

Website

https://www.bioxceltherapeutics.com

BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

Executives

Richard I Steinhart	officer: Chief Financial Officer	125 ELM STREET, NEW CANAAN CT 06840
Javier Rodriguez	officer: SEE REMARKS	C/O BIOXCEL THERAPEUTICS, INC., 555 LONG WHARF DRIVE, NEW HAVEN CT 06511
Frank Yocca	officer: Chief Scientific Officer	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vimal Mehta	director, officer: CEO, President, Secretary	780 EAST MAIN STREET, C/O BIOXCEL THERAPEUTICS, INC., BRANFORD CT 06405
Vincent O'neill	officer: Chief Medical Officer	2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744
Matthew T. Wiley	officer: CHIEF COMMERCIAL OFFICER	C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402
Krishnan Nandabalan	director, 10 percent owner	228 VILLAGE POND ROAD, GUILFORD CT 06437
Alka Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Michael James Aiello	10 percent owner	10 TEMPLETON ROAD, WALLINGFORD CT 06492
Pardeep Kumar Sood	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Vipin Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Rashmi Agarwal	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Jatin Markand Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Bina Jatin Patel	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437
Diwakar Jain	10 percent owner	2614 BOSTON POST ROAD, SUITE #33B, GUILFORD CT 06437